393 related articles for article (PubMed ID: 24991376)
1. The economics of biosimilars.
Blackstone EA; Joseph PF
Am Health Drug Benefits; 2013 Sep; 6(8):469-78. PubMed ID: 24991376
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
3. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
5. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
7. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
8. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
9. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.
Mulcahy AW; Hlavka JP; Case SR
Rand Health Q; 2018 Mar; 7(4):3. PubMed ID: 30083415
[TBL] [Abstract][Full Text] [Related]
10. Biologic Drugs, Biosimilars, and Barriers to Entry.
Shepherd JM
Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
[TBL] [Abstract][Full Text] [Related]
11. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
13. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
14. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
16. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
17. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: Review of current applications, obstacles, and their future in medicine.
Kaida-Yip F; Deshpande K; Saran T; Vyas D
World J Clin Cases; 2018 Aug; 6(8):161-166. PubMed ID: 30148143
[TBL] [Abstract][Full Text] [Related]
20. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
Dolinar R; Lavernia F; Edelman S
Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]